New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 30, 2012
09:59 EDTKUB, STJ, DFT, RY, WAC, LMT, CAG, BRO, ULTA, HMSY, CBM, BELFB, ACTVOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Active Network (ACTV) upgraded to Buy from Underperform at BofA/Merrill... Bel Fuse (BELFB) upgraded to Buy from Hold at Needham... Cambrex (CBM) upgraded to Buy from Neutral at Longbow... ConAgra (CAG) upgraded to Buy from Hold at Jefferies... DuPont Fabros (DFT) upgraded to Outperform from Sector Perform at RBC Capital... HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies... Lockheed Martin (LMT) upgraded to Fair Value from Sell at CRT Capital... St. Jude Medical (STJ) upgraded to Buy from Neutral at Mizuho... Ulta Salon (ULTA) upgraded to Outperform from Market Perform at Wells Fargo... Walter Investment (WAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Kubota Limited (KUB) upgraded to Buy from Neutral at BofA/Merrill... Brown & Brown (BRO) upgraded to Outperform from Neutral at Macquarie... Royal Bank of Canada (RY) upgraded to Outperform from Neutral at Macquarie.
News For ACTV;BELFB;CBM;CAG;DFT;HMSY;LMT;STJ;ULTA;WAC;KUB;BRO;RY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
09:51 EDTBELFBBel Fuse management to meet with Stephens
Meetings to be held in Cleveland on March 24 and in Milwaukee on March 25 hosted by Stephens.
06:10 EDTULTAUlta Salon implied volatility of 23 at lower end of index mean range
March 19, 2015
11:18 EDTDFTDuPont Fabros management to meet with Jefferies
Subscribe for More Information
10:42 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
10:02 EDTHMSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 18, 2015
17:19 EDTHMSYHMS Holdings initiated with an Outperform at RW Baird
Subscribe for More Information
11:44 EDTWACOcwen reopens after announcing MSR deal with Walter Investment
Ocwen (OCN) shares are up fractionally shortly after reopening for trading.
11:37 EDTWACWalter Investment jumps 7% after subsidiary agrees to buy MSRs from Ocwen
11:36 EDTWACOcwen intends to sell $9.6B portfolio of mortgage servicing rights to Green Tree
Subscribe for More Information
11:35 EDTWACOcwen intends to sell $9.6B portfolio of mortgage servicing rights to Green Tree
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:16 EDTBROJPMorgan to hold a conference
Subscribe for More Information
05:39 EDTSTJSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
14:41 EDTLMTLockheed Martin nearing F-16 upgrade deal with Singapore, Defense News says
Subscribe for More Information
10:13 EDTULTAOptions with decreasing implied volatility
Subscribe for More Information
07:18 EDTLMTSatellite & Access Intelligence to hold a exhibition
Subscribe for More Information
06:02 EDTULTAUlta Salon implied volatility of 23 at lower end of index mean range
Subscribe for More Information
March 16, 2015
13:16 EDTSTJAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
10:14 EDTULTAOptions with decreasing implied volatility
Options with decreasing implied volatility: EXPR ULTA SGMS QIHU BKS PAY URBN AGN AGNC
08:05 EDTSTJSt. Jude Medical data 'impressive,' says BMO Capital
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use